TYK-ing all the boxes in psoriasis - 03/06/22
Doi : 10.1016/j.jaci.2022.03.014
Christoph Schlapbach, MD, PhD a, Curdin Conrad, MD b, ⁎ 
a Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
b Department of Dermatology, CHUV University Hospital and University of Lausanne, Lausanne, Switzerland
∗Corresponding author: Curdin Conrad, MD, Department of Dermatology, CHUV University Hospital and University of Lausanne, Lausanne, Switzerland.Department of DermatologyCHUV University Hospital and University of LausanneLausanneSwitzerland
Key words : TYK2, TYK2 inhibitor, deucravacitinib, psoriasis, IL-23, TH17, IL-17, type I interferon, IFN, JAK, JAK inhibitor
Le texte complet de cet article est disponible en PDF.
| Disclosure of potential conflict of interest: C. Schlapbach has received honoraria as an adviser from Abbvie, LEO Pharma, Lilly, and Novartis and has received research funding from PPM Services. C. Conrad has received honoraria as an adviser from AbbVie, Actelion, Almirall, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Galderma, Incyte, Janssen, LEO Pharma, MSD, Novartis, Pfizer, Samsung, and UCB. |
© 2022
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 149 - N° 6
P. 1936-1939 - juin 2022 Retour au numéro
Article précédent
- News Beyond Our Pages
- Marc E. Rothenberg, Jean Bousquet
- How are airborne allergens remembered by the immune system?
- Hirohito Kita
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?